Spring direct naar de hoofdnavigatie of de inhoud

Frits Michiels

Patent attorney

“To explore, together with a client, how the best IP protection can be obtained is for me the logical next step after an invention has been made.”
Home / Experts / Frits Michiels

Frits Michiels

Frits Michiels

  • Life Sciences
  • European Patent Attorney
  • Dutch Patent Attorney
  • Senior Associate

Frits Michiels has had an extensive scientific career in both knowledge institutes and biotech companies. From 2004, he was employed as IP manager at Galapagos Genomics BV and subsequently also at other Dutch biotech startups, such as Agendia and Merus. He has worked for V.O. since 2006.

More information about Frits

He is specialized in biochemistry, molecular biology, cell biology, diagnostics, signal transduction, and medical biotechnology. His clients are primarily knowledge institutes and start ups. He is involved in patent prosecution and strategic advice.

Working experience

  • Patent Attorney, V.O. (2006-present)
  • Merus (2006)
  • Galapagos Genomics (1999-2005)
  • Senior Scientist at the Netherlands Cancer Institute (1994-1998)
  • Post-Doc, Amsterdam Medical Center (1991-1993)
  • PhD research at Max Planck Institute for Biochemistry, Munich (1985-1990)

Education

  • PhD in Genetics, Radboud University Nijmegen (1990)
  • MSc in Microbiology, Radboud University Nijmegen (1984)

Publications

  • Michiels, GAM Damages extended to after termination of a tort. MIP Vol 205: 94-95 (2011)
  • JP ten Klooster, EE Evers, L Janssen, LM Machesky, F Michiels, P Hordijk and JG Collard. Biochem J. 397, 39–45 (2006)
  • GJ Arts, E Langemeijer, R Tissingh, L Ma, H Pavliska, K Dokic, R Dooijes, E Mesić, R Clasen, F Michiels, J van der Schueren, M Lambrecht, S Herman, R Brys, K Thys, M Hoffmann, P Tomme, H van Es. Genome Res 13, 2325-32 (2003)
  • A Malliri, RA van der Kammen, K Clark, M van der Valk, F Michiels & JG Collard. Nature 417, 867-871 (2002)
  • F Michiels et al. Nature Biotech 20, 1154-1157 (2002)
  • R Engers, E Springer, F Michiels, JG Collard, HE Gabbert. J Biol Chem 276, 41889-97 (2001)
  • WO2002057463 Swap/counter selection; a rapid cloning
  • WO2002070744 Adenoviral library assay for E2F regulatory genes and methods and compositions for screening compounds method
  • WO2005124342 Methods and means for treatment of osteoarthritis

Languages

  • English
  • Dutch
  • German

Also see these experts

Mark Einerhand

  • European Patent Attorney
  • Dutch Patent Attorney
  • Partner

Jennifer Ebner von Eschenbach

  • European Patent Attorney
  • Senior Associate
More experts

News

IP Academy well attended

This year’s IP Academy was scheduled between 1 and 15 November and saw broad participation from all sectors of our Dutch client database.Continue reading

Plants can be patentable after all

Classically bred plants should be held patentable once again. Last Wednesday the EPO Board of Appeal came to this remarkable decision. On July 1st last year the EPO – on explicit advice by the European member states – introduced guidelines that seemed to definitely exclude plants obtained by an essentially biological process from patentability. But […]Continue reading

The Ocean Cleanup at work

After an extensive trial phase with a U-shaped tube system, The Ocean Cleanup has finally begun to sweep the ocean clean, under the charismatic leadership of Boyan Slat. This all took place under an intense media spotlight.Continue reading

Events

Innovation for Health

World Trade Center (WTC) Rotterdam, Beursplein, Rotterdam

Innovation for Health is the premier event for key players in Health & Life Sciences in the Netherlands and Belgium. It provides a unique opportunity to meet leading innovators, to catch up on the latest trends, to present cutting-edge innovations and to engage leaders and decision makers in Life Sciences & Health. More about this event

Knowledge for Growth 2019

Gent ICC, Gent, België

Don’t miss the 2019 edition on 9 May  and capture the attention of 1,200 high-level life sciences actors from about 550 companies & organisations! The cream of the European life sciences community will be attending the 15th edition of flanders.bio’s annual knowledge for growth business conference, attracting decision makers from biotech, pharma and medtech as well as investors, universities, topnotch research institutes, policymakers and competence providers. More about this event